GLAXOSMITHKLINE CONSUMER NIGERIA PLC GLAXOSMITHKLINE CONSUMER NIGERIA PLC
UNAUDITED CONDENSED CONSOLIDATED AND SEPARATE FINANCIAL
STATEMENTS
FOR THE 6 MONTHS PERIOD ENDED 30 JUNE 2023
GlaxoSmithKline Consumer Nigeria Plc
Condensed unaudited consolidated and seperate financial statements
For the 6 months period ended 30 June 2023
Table of Contents | Page |
Condensed unaudited consolidated and separate statement of profit or loss and other comprehensive income | 1 |
Condensed unaudited consolidated and separate statement of financial position | 2 |
Condensed unaudited consolidated and separate statement of changes in equity | 4 |
Condensed unaudited consolidated and separate statement of cash flows | 5 |
Shareholding structure and free float status | 6 |
Notes to the unaudited condensed consolidated and separate financial statements | 7 |
GlaxoSmithKline Consumer Nigeria Plc
Condensed unaudited consolidated and separate statement of profit or loss and other comprehensive income For the 6 months period ended 30 June 2023
GROUP
COMPANY
3 months ended
Revenue
Cost of sales
Gross profit
Selling and distribution costs Administrative expenses Finance income
Other gains and (losses) Impairment loss on financial assets
Profit before tax
Current tax expense
Apr - June
2023
N'000
3,731,801
(2,417,612)
1,314,189
(693,426)
(497,310)
192,287
(28,185)
(13,809)
273,746
(89,195)
Apr - June
2022
N'000
7,451,236
(5,665,010)
1,786,226
(1,099,340)
(453,501)
18,430
(7,327)
(12,766)
231,722
(76,739)
Apr - June
2023
N'000
3,731,801
(2,417,612)
1,314,189
(693,426)
(496,640)
192,287
(28,185)
(13,809)
274,416
(89,195)
Apr - June
2022
N'000
7,451,236
(5,665,010)
1,786,226
(1,099,340)
(452,873)
18,430
(7,327)
(12,766)
232,350
(76,947)
Profit for the period
Profit for the period attributable to:
Shareholders of the Company
Non-controlling interest
Total comprehensive income for the period attributable to: Shareholders of the Company
Non-controlling interest
Basic and diluted earnings per share (Kobo)
184,551 | 154,983 | |
184,551 | 154,983 | |
- | - | |
184,551 | 154,983 | |
184,551 | 154,983 | |
- | - | |
184,551 | 154,983 | |
15 | 13 | |
185,221 | 155,403 | |
185,221 | 155,403 | |
- | - | |
185,221 | 155,403 | |
185,221 | 155,403 | |
- | - | |
185,221 | 155,403 | |
16 | 13 | |
1
GlaxoSmithKline Consumer Nigeria Plc
Condensed unaudited consolidated and separate statement of profit or loss and other comprehensive income For the 6 months period ended 30 June 2023
GROUP |
COMPANY
Jan - Jun | Jan - Jun | |||
6 months ended | 2023 | 2022 | ||
Notes | N'000 | N'000 | ||
Revenue | 5 | 7,750,878 | 14,811,269 | |
Cost of sales | 6 | (4,958,231) | (11,066,784) | |
Gross profit | 2,792,647 | 3,744,485 | ||
Selling and distribution costs | 7 | (1,432,899) | (2,169,699) | |
Administrative expenses | 7 | (1,070,204) | (1,005,771) | |
Finance income | 8 | 270,285 | 44,747 | |
Other gains and (losses) | 9 | (35,191) | (71,037) | |
Impairment loss on financial assets | 18.3 | (20,707) | (25,169) | |
Profit before tax | 503,931 | 517,556 | ||
Current tax expense | 11.1 | (164,209) | (168,206) | |
Profit for the period | 339,722 | 349,350 | ||
Other comprehensive income net of | ||||
income tax: | ||||
Items that will not be reclassified to |
Jan - Jun
2023
N'000
7,750,878
(4,958,231)
2,792,647
(1,432,899)
(1,068,906)
270,285
(35,191)
(20,707)
505,229
(164,209)
341,020
Jan - Jun
2022
N'000
14,811,269
(11,066,784)
3,744,485
(2,169,699)
(1,004,514)
44,747
(71,037)
(25,169)
518,813
(168,615)
350,198
profit or loss: | - | - | ||
- | - | |||
Total comprehensive income for the | ||||
period, net of tax | 339,722 | 349,350 | ||
Profit for the period attributable to: | ||||
Shareholders of the Company | 339,722 | 349,350 | ||
Non-controlling interest | - | - | ||
339,722 | 349,350 | |||
Total comprehensive income for the | ||||
period attributable to: | ||||
Shareholders of the Company | 339,722 | 349,350 | ||
Non-controlling interest | - | - | ||
339,722 | 349,350 | |||
Basic and diluted / earnings per share | ||||
(Kobo) | 12 | 28 | 29 | |
- | - | |
- | - | |
341,020 | 350,198 | |
341,020 | 350,198 | |
- | - | |
341,020 | 350,198 | |
341,020 | 350,198 | |
- | - | |
341,020 | 350,198 | |
29 | 29 | |
2
GlaxoSmithKline Consumer Nigeria Plc
Condensed unaudited consolidated and separate statement of financial position As at 30 June 2023
GROUP | ||||||
As at 30 | As at 31 | As at 30 | ||||
June 2023 | December 2022 | June 2022 | ||||
Notes | N'000 | N'000 | N'000 | |||
Assets | ||||||
Non-current assets | ||||||
Deferred tax asset | 11.3 | 413,802 | 413,802 | 231,223 | ||
Property, plant and equipment | 13 | 348,993 | 441,245 | 495,284 | ||
Investment property | 14 | 526,972 | 529,302 | 583,203 | ||
Investment in subsidiary | 16 | - | - | - | ||
1,289,767 | 1,384,349 | 1,309,710 | ||||
Current assets |
COMPANY
As at 30 | As at 31 | As at 30 | ||
June 2023 | December 2022 | June 2022 | ||
N'000 | N'000 | N'000 | ||
413,802 | 413,802 | 231,223 | ||
348,993 | 441,245 | 495,284 | ||
526,972 | 529,302 | 583,203 | ||
- | - | 160 | ||
1,289,767 | 1,384,349 | 1,309,870 |
Inventories | 17 | 2,182,243 | 3,739,540 | 5,205,618 | 2,182,243 | 3,739,540 | 5,205,618 | |||||
Trade and other receivables | 18 | 3,303,178 | 3,847,810 | 6,281,906 | 3,303,178 | 3,847,810 | 6,281,906 | |||||
Other assets | 19 | 126,081 | 63,167 | 169,023 | 126,081 | 63,167 | 169,023 | |||||
Cash and cash equivalents | 20 | 23,214,990 | 19,976,023 | 12,877,541 | 23,214,990 | 19,976,023 | 12,877,541 | |||||
28,826,492 | 27,626,540 | 24,534,088 | 28,826,492 | 27,626,540 | 24,534,088 | |||||||
Assets classified as held for sale | 15 | 151,757 | 375,315 | 691,462 | 151,757 | 375,315 | 691,462 | |||||
28,978,249 | 28,001,855 | 25,225,550 | 28,978,249 | 28,001,855 | 25,225,550 | |||||||
Total assets | 30,268,016 | 29,386,204 | 26,535,260 | 30,268,016 | 29,386,204 | 26,535,420 | ||||||
Equity and liabilities | ||||||||||||
Equity | ||||||||||||
Issued share capital | 21.1 | 597,939 | 597,939 | 597,939 | 597,939 | 597,939 | 597,939 | |||||
Share premium | 21.2 | 51,395 | 51,395 | 51,395 | 51,395 | 51,395 | 51,395 | |||||
Retained earnings | 8,565,108 | 8,883,118 | 8,461,322 | 8,402,275 | 8,718,987 | 8,292,826 | ||||||
9,214,442 | 9,532,452 | 9,110,656 | 9,051,609 | 9,368,321 | 8,942,160 | |||||||
Non-current liabilities | ||||||||||||
Liability for share-based payments | 24 | - | 8,768 | 26,279 | - | 8,768 | 26,279 | |||||
- | 8,768 | 26,279 | - | 8,768 | 26,279 | |||||||
Current liabilities | ||||||||||||
Trade and other payables | 22 | 20,845,452 | 19,145,605 | 17,197,215 | 21,022,031 | 19,323,482 | 17,379,208 | |||||
Contract liabilities | 23 | - | 11,065 | - | - | 11,065 | - | |||||
Liability for share-based payments | 24 | 8,282 | - | - | 8,282 | - | - | |||||
Current tax liabilities | 11.2 | 199,840 | 688,314 | 201,110 | 186,094 | 674,568 | 187,773 | |||||
Total current liabilities | 21,053,574 | 19,844,984 | 17,398,325 | 21,216,407 | 20,009,115 | 17,566,981 | ||||||
Total liabilities | 21,053,574 | 19,853,752 | 17,424,604 | 21,216,407 | 20,017,883 | 17,593,260 | ||||||
Total equity and liabilities | 30,268,016 | 29,386,204 | 26,535,260 | 30,268,016 | 29,386,204 | 26,535,420 | ||||||
The condensed unaudited consolidated and separate financial statements for the six months period ended 30 June 2023 were approved and authorised for issue by the Board of Directors on 2 August 2023 and signed on its behalf by:
Mr. Edmund C. Onuzo | Mr. Olakunle Azeez Oyelana | Bosco Kirugi | ||
Chairman | Managing Director | Finance Director | ||
FRC/2015/IODN/00000011038 | FRC/2020/003/00000020395 | FRC/2022/PRO/DIR/003/956071 |
3
| Attention: This is an excerpt of the original content. To continue reading it, access the original document here. |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Glaxo Smithkline Consumer Nigeria plc published this content on 03 August 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 August 2023 08:39:02 UTC.
